Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1269)	3/6/2002 9:10:52 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

Appears now that even China is catching up and maybe passing all with their stem-cell research....http://www.msnbc.com/news/720020.asp Way to go....American politicians and right wingers!

To: scaram(o)uche who wrote (1269)	3/15/2002 2:30:27 PM
From: Arthur Radley	Respond to of 1475

CryoLife, Inc. Replies to Recent Articles and Announces Conference Call At 12:45 pm Today ATLANTA, March 15 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY - news), a life-science company involved in the development and commercialization of tissue-engineered implantable heart valves, vascular and orthopaedic grafts, and surgical adhesives, today replied to an announcement by the CDC regarding certain human tissue allograft transplants. Steven G. Anderson, President and CEO commented, ``The report of twenty six infections in tissue transplants released by the CDC this morning relates to tissue processed by four or five tissue banks across the U.S. and represents events dating back as far as 1998. Some of the infections are likely not to be due to the tissue itself and may be infections transmitted from other sources. There is no epidemic of infections from tissue processed from tissue banks throughout the U.S. CryoLife has provided over 25,000 orthopaedic allograft soft tissue implants with more than 6,700 orthopaedic allograft soft tissue implants performed during 2001. The reported incidence of infection since 1998 from all causes associated with CryoLife orthopaedic soft tissue implants is less than two-tenths of one percent of 2001 implants.'' Anderson went on to say, ``Patient safety is paramount at CryoLife. CryoLife has taken all suggestions from the CDC seriously and has implemented those that it can at this time. CryoLife continues to evaluate improvements to its processes.